Market Intelligence, Clinical Progress, and High-Purity Reagents for Congenital Disorders of Glycosylation (CDG) and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TMEM165 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TMEM165 Hydrophilic Loop Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View TMEM165 Products |
| Gene Delivery | TMEM165 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for multi-pass membrane conformation preservation. |
View TMEM165 Products |
| Benchmark Ab | Anti-TMEM165 Recombinant Antibody Recombinant positive control derived from public research sequences. |
View TMEM165 Products |
| Validator | TMEM165 siRNA Set For knockdown verification in functional assays. |
View TMEM165 Products |
| Related Target A | SLC39A8 Synergistic manganese transporter; crucial for counter-screening and dual-targeting pathway analysis. |
View SLC39A8 Products |
| Related Target B | B4GALT1 Downstream galactosyltransferase directly affected by TMEM165-mediated manganese homeostasis. |
View B4GALT1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass Membrane Conformation Loss | Lentiviral transduction vectors ensure stable expression in host cell lines, maintaining native 6-transmembrane topology. |
| Subfamily & Transporter Counter-Screening | Ortholog and related transporter panel proteins (e.g., SLC39A8) strictly verified by mass spectrometry. |
| Lack of Reference Controls | Sequence-verified clinical-grade benchmark recombinant antibodies included. |
| Off-Target / False Positives | In vitro validated siRNA sets included for target-specific gene knockdown controls. |
Live TMEM165 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of TMEM165 (Transmembrane Protein 165) is an emerging frontier spanning congenital disorders of glycosylation (CDG-IIk) and oncology. As a critical regulator of Golgi manganese (Mn2+) and calcium (Ca2+) homeostasis, TMEM165 deficiency disrupts protein glycosylation, leading to severe systemic pathology. Conversely, TMEM165 overexpression is increasingly documented in invasive cancers (e.g., breast cancer), where it drives aberrant glycosylation of key surface receptors like EGFR and E-cadherin, promoting metastasis.
The race for TMEM165 therapeutics is intensifying, with major players shifting focus from traditional mAbs to small-molecule ion transport inhibitors and gene therapy vectors. As first-generation therapies reach the clinic, the next wave of R&D is targeting precise modulation of Golgi glycosylation pathways to bypass drug resistance and mitigate off-target toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | Breast Cancer, Osteosarcoma | Ion Transport & Selectivity Assay (Need Lentivirus for Stable Cell Lines) |
| Gene Therapy (AAV/Lentivirus) | Rare Disease Consortia, Gene Therapy Developers | CDG-IIk (Congenital Disorder of Glycosylation) | Functional Rescue Validation (Need TMEM165 siRNA & Pathway Targets) |
| Monoclonal Antibodies | Oncology-focused Biopharma | Metastatic Solid Tumors | Epitope Mapping & Binding Affinity (Need High-Purity Loop Recombinants) |